Aswar Urmila, Shintre Sumit, Chepurwar Shilpa, Aswar Manoj
Department of Pharmacology, Sinhgad Institute of Pharmacy , Pune, Maharashtra , India.
Pharm Biol. 2015;53(9):1358-66. doi: 10.3109/13880209.2014.982299. Epub 2015 Apr 14.
Allergic rhinitis (AR) is a global health problem that affects a large number of population. Piperine (PIP) has been reported to exhibit anti-inflammatory, anti-histaminic, and immunomodulatory activities; however, its antiallergic profile has not been studied.
The objective of the study was to investigate the antiallergic potential of PIP in ova-albumin (OVA)-induced AR, mast cell degranulation (MSD), and OVA-induced paw edema.
Mice were sensitized with OVA alternately on 1, 3, 5, 7, 9, 11, and 13th day. They were treated with either vehicle, PIP (10, 20, and 40 mg/kg, p.o.), or montelukast (10 mg/kg, p.o.) from the 14th to 20th day. On the 21st day, intranasal (OVA: 5% µl) challenge was done. Animals were evaluated for physiological parameters, biochemical parameters, spleen weight, expression of interleukins (IL-6 and IL-1β), and immunoglobin-E (IgE). Histopathology of nasal mucosa, lungs, and spleen was carried out. MSD and paw edema studies were made to understand the mechanism of action.
PIP (10, 20, and 40 mg/kg, p.o.) showed a significant dose-dependent protection with respect to nasal rubbing, redness of nose, and sneezing (p < 0.001) following nasal challenge. PIP dose dependently reduced histamine, NO concentration (p < 0.001), as well as reduced expression of IL-6, IL-1β, and IgE (p < 0.001) as compared with the control group. Histopathology showed inhibition of infiltration of eosinophils and hyperplasia. It dose dependently reduced MSD and paw edema (p < 0.001).
PIP acts by mast cell-stabilizing activity, exhibits immunomodulatory and anti-inflammatory activity, thereby providing an effective treatment for AR.
变应性鼻炎（AR）是一个影响大量人群的全球健康问题。据报道，胡椒碱（PIP）具有抗炎、抗组胺和免疫调节活性；然而，其抗过敏特性尚未得到研究。
本研究的目的是探讨PIP在卵清蛋白（OVA）诱导的AR、肥大细胞脱颗粒（MSD）和OVA诱导的爪部水肿中的抗过敏潜力。
在第1、3、5、7、9、11和13天用OVA对小鼠进行交替致敏。从第14天到第20天，给它们分别用赋形剂、PIP（10、20和40mg/kg，口服）或孟鲁司特（10mg/kg，口服）进行治疗。在第21天，进行鼻内（OVA：5%μl）激发。对动物的生理参数、生化参数、脾脏重量、白细胞介素（IL-6和IL-1β）和免疫球蛋白E（IgE）的表达进行评估。对鼻黏膜、肺和脾脏进行组织病理学检查。进行MSD和爪部水肿研究以了解其作用机制。
PIP（10、20和40mg/kg，口服）在鼻激发后，在鼻摩擦、鼻发红和打喷嚏方面显示出显著的剂量依赖性保护作用（p<0.001）。与对照组相比，PIP剂量依赖性地降低了组胺、NO浓度（p<0.001），以及降低了IL-6、IL-1β和IgE的表达（p<0.001）。组织病理学显示嗜酸性粒细胞浸润和增生受到抑制。它剂量依赖性地降低了MSD和爪部水肿（p<0.001）。
PIP通过肥大细胞稳定活性发挥作用，表现出免疫调节和抗炎活性，从而为AR提供了一种有效的治疗方法。
